Product details
Background：Tabalumab is a humanized IgG4 monoclonal antibody that targets b-cell activating factor (BAFF/Blys/TNFSF13B) , inhibits its binding to b-cell receptors by neutralizing soluble and membrane-bound BAFF, and inhibits its binding to b-cell receptors, thus, it can regulate the activation, proliferation and antibody production of B cells, and has potential value in the treatment of autoimmune diseases. As a BAFF inhibitor developed by Eli Lilly, its mechanism of action focuses on blocking BAFF-mediated b-cell survival signals, reducing abnormal autoantibody production, and reducing the risk of BAFF-mediated apoptosis, in theory, it could be used to treat diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
